Thoracic Aortic Surgery Program
Founded in 1993, the Penn
Thoracic Aortic Surgery Program is
the first comprehensive program
of its kind in the Philadelphia region.
Led by nationally and internationally
recognized cardiovascular surgeons
Joseph
E. Bavaria, MD, Alberto
Pochettino, MD, Wilson
Y. Szeto, MD,
and vascular surgeons Ronald
M. Fairman, MD, Jeffrey
Carpenter, MD,
and Edward Y. Woo,
MD, the Program
performed 347 aortic and thoracic
procedures in 2006 alone.
Wilson Szeto, MD, exemplifies the
training mission of the Division of
Cardiovascular Surgery. Dr. Szeto
served his residency in cardiothoracic
surgery and research at Penn, and
expanded the thoracic aortic surgical
team to Penn Presbyterian Medical
Center in 2006.
Since 1993, the Penn Thoracic Aortic
Surgery Program has increased
dramatically in scope and volume.
Penn treats four times more
patients with aortic aneurysms than
any other hospital in the region. |
|
Distribution of
Thoracic Aortic Surgeries in 2006 |
|
|
Thoracic
Endovascular Aortic Repair (TEVAR) |
Penn
is one of only seven programs actively
educating and training surgeons throughout
the United States in an FDA mandated
curriculum to perform device specific
endovascular stent procedures for
thoracic aortic aneurysms. Between
the years 2002-2006, Penn surgeons
performed 244 endovascular stent
procedures with outcomes ranking
among the best in the nation.
|
|
|
TEVAR: Treatment for
Acute Aortic Syndrome
|
Penn surgeons led patient
enrollment in the FDA trial aimed
at expanding the indications for
endovascular stent graft repair for
patients with acute Type B aortic
dissections, traumatic transections,
or aneurysmal rupture.
At Penn, endovascular repair has
emerged as the surgical therapy
of choice for acute Type B aortic
dissection complicated by rupture
or malperfusion syndrome,
representing a dramatic change in
therapeutic paradigm. Long term
investigation is needed to examine
the effect of TEVAR on the fate of
distal aorta in aortic remodeling.
Penn's 30-day mortality rate is
3.57% and 1-year survival rate is
92.4%. |
|
|
